RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor is under clinical development by Gradalis and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor overview
RNAi gene therapy is under development for the treatment of solid tumor. The drug candidate is administered by intratumoral injection. The therapeutic candidate is a RNA interference construct consisting of bifunctional short hairpin RNAs (shRNA) against human stathmin 1 (STMN1) encapsulated in the cationic bilamellar invaginated vesicle lipoplex (LP) with potential antineoplastic activity.
Gradalis overview
Gradalis formerly Murex Pharmaceuticals is a biotechnology company that develops and commercializes novel therapies for the treatment of cancer. The company’s product pipeline includes autologous cancer vaccines, IO combinations and genes proteins for treating Ewing’s sarcoma, ovarian, breast, melanoma, solid tumors, lung, hepatocellular and colorectal cancer. Its proprietary immunotherapy platform, vigil is utilized in various advanced cancer indications and helps in stimulating and improving the body’s natural mechanism for identifying and killing cancer cells. Gradalis is headquartered in Carrollton, Texas, the US.
For a complete picture of RNAi Gene Therapy to Inhibit STMN1 for Solid Tumor’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
